Extrapulmonary small cell carcinoma localized in lymph nodes: Is it a different clinical entity?

Basit Öğe Kaydı
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authorwosidKocak, Zafer/AEG-7828-2022
dc.authorwosidCicin, Irfan/AAQ-5575-2020
dc.contributor.authorCicin, Irfan
dc.contributor.authorUsta, Ufuk
dc.contributor.authorKaragol, Hakan
dc.contributor.authorUzunoglu, Sernaz
dc.contributor.authorKocak, Zafer
dc.date.accessioned2024-06-12T11:20:04Z
dc.date.available2024-06-12T11:20:04Z
dc.date.issued2009
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground. Extrapulmonary small cell carcinomas (EPSCC) can clinically progress differently depending on the primary site of disease involvement. This review is focused on patients with small cell carcinoma (SmCC) exclusively localized in a lymph node or in multiple lymph nodes without any evidence of a primary tumor in any other organ. Methods. We searched the period 1980 to 2007 in the PubMed database and idendified 11 publications in the English language presenting at least one case of SmCC. In total 28 individual patients were included in the present study. They were scrutinized in terms of epidemiology, clinical presentation, staging, pathology, etiology, treatment and prognosis. Results. Characteristics such as age, gender and smoking were similar to those seen in other EPSCCs. Median survival was not reached (42+, range, 9.1 to 100 months). The survival rate was found to be 79% at 3 years. Seventy-seven percent of the patients had limited stage disease. These patients completely responded to surgical therapy, chemotherapy, radiotherapy or to a combination of these treatments. Seventy-one percent of the patients with limited stage SmCC localized in lymph nodes were recurrence-free during the study periods. Discussion. Our review patient group with SmCC localized in lymph nodes exhibited an excellent clinical behavior and survival results when compared to other patients with pulmonary and non-pulmonary SmCCs. SmCCs localized in lymph nodes may be a separate clinical entity.en_US
dc.identifier.doi10.1080/02841860802495370
dc.identifier.endpage360en_US
dc.identifier.issn0284-186X
dc.identifier.issn1651-226X
dc.identifier.issue3en_US
dc.identifier.pmid18979286en_US
dc.identifier.scopus2-s2.0-65349105944en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage354en_US
dc.identifier.urihttps://doi.org/10.1080/02841860802495370
dc.identifier.urihttps://hdl.handle.net/20.500.14551/25458
dc.identifier.volume48en_US
dc.identifier.wosWOS:000264266500004en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofActa Oncologicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectTherapyen_US
dc.subjectCanceren_US
dc.subjectExperienceen_US
dc.subjectBiologyen_US
dc.titleExtrapulmonary small cell carcinoma localized in lymph nodes: Is it a different clinical entity?en_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu